Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04144257
PHASE1/PHASE2

Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue

Sponsor: Brigham and Women's Hospital

View on ClinicalTrials.gov

Summary

The overarching aim is to assess the role of microglial activation and norepinephrine transporter binding in pathogenesis of MS-related fatigue, using novel Positron Emission Tomography (PET) radiotracers, \[F-18\]PBR06 and \[C-11\]MRB. Specific Aims: Specific Aim 1: To determine the relationship of cerebral microglial activation, as assessed by \[F-18\]PBR06 PET, with MS-related fatigue. Specific Aim 2: To determine the relationship of norepinephrine transporter (NET) binding, as assessed by \[C-11\]MRB PET, with MS-related fatigue. Specific Aim 3: To determine the relationship of microglial activation and NET binding, with grey matter pathology (lesion load and brain atrophy) assessed using 7T MRI, and evaluate their independent contribution in development of MS-related fatigue.

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2020-03-12

Completion Date

2021-04-13

Last Updated

2026-05-04

Healthy Volunteers

No

Interventions

DRUG

[F-18]PBR06

PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).

DRUG

[C-11]Methylreboxetine

PET radiopharmaceutical. Subjects will undergo \[C-11\]MRB-PET (norepinephrine transporter binding).

Locations (1)

Brigham MS Center, 60 Fenwood Road

Boston, Massachusetts, United States